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BACKGROUND
The role of neoadjuvant chemoradiotherapy in the treatment of patients with esopha-
geal or esophagogastric-junction cancer is not well established. We compared chemo-
radiotherapy followed by surgery with surgery alone in this patient population.
METHODS
We randomly assigned patients with resectable tumors to receive surgery alone or 
weekly administration of carboplatin (doses titrated to achieve an area under the 
curve of 2 mg per milliliter per minute) and paclitaxel (50 mg per square meter of 
body-surface area) for 5 weeks and concurrent radiotherapy (41.4 Gy in 23 fractions, 
5 days per week), followed by surgery.
RESULTS
From March 2004 through December 2008, we enrolled 368 patients, 366 of whom 
were included in the analysis: 275 (75%) had adenocarcinoma, 84 (23%) had squa-
mous-cell carcinoma, and 7 (2%) had large-cell undifferentiated carcinoma. Of the 
366 patients, 178 were randomly assigned to chemoradiotherapy followed by surgery, 
and 188 to surgery alone. The most common major hematologic toxic effects in the 
chemoradiotherapy–surgery group were leukopenia (6%) and neutropenia (2%); the 
most common major nonhematologic toxic effects were anorexia (5%) and fatigue (3%). 
Complete resection with no tumor within 1 mm of the resection margins (R0) was 
achieved in 92% of patients in the chemoradiotherapy–surgery group versus 69% in 
the surgery group (P<0.001). A pathological complete response was achieved in 47 of 
161 patients (29%) who underwent resection after chemoradiotherapy. Postoperative 
complications were similar in the two treatment groups, and in-hospital mortality was 
4% in both. Median overall survival was 49.4 months in the chemoradiotherapy–
surgery group versus 24.0 months in the surgery group. Overall survival was sig-
nificantly better in the chemoradiotherapy–surgery group (hazard ratio, 0.657; 95% 
confidence interval, 0.495 to 0.871; P = 0.003).
CONCLUSIONS
Preoperative chemoradiotherapy improved survival among patients with potentially 
curable esophageal or esophagogastric-junction cancer. The regimen was associated 
with acceptable adverse-event rates. (Funded by the Dutch Cancer Foundation [KWF 
Kankerbestrijding]; Netherlands Trial Register number, NTR487.)
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With new diagnoses in more than 480,000 patients annually, esophageal cancer is the eighth most common can-
cer worldwide.1 It is a highly lethal disease, causing 
more than 400,000 deaths per year.2 The incidence 
of esophageal adenocarcinoma is rapidly rising, 
whereas that of squamous-cell carcinoma remains 
unchanged.3 Despite adequate preoperative stag-
ing, 25% of patients treated with primary sur-
gery have microscopically positive resection mar-
gins (R1), and the 5-year survival rate rarely 
exceeds 40%.4
The role of neoadjuvant chemoradiotherapy has 
been debated for several decades. In most random-
ized trials, no survival benefit could be shown, and 
the trials were criticized for inadequate trial de-
sign, samples that were too small, and poor out-
comes in the surgery-alone group. Meta-analyses 
suggest a survival benefit from neoadjuvant chemo-
radiotherapy, albeit frequently at the cost of in-
creased postoperative morbidity and mortality.5,6
We previously reported a phase 2 trial of neo-
adjuvant chemoradiotherapy consisting of weekly 
administration of carboplatin and paclitaxel with 
concurrent radiotherapy.7 This regimen was as-
sociated with a low rate of serious toxic effects, 
and a complete resection with no tumor within 
1 mm of the resection margins (R0) was achieved 
in all patients who underwent resection. These re-
sults encouraged us to initiate a multicenter, ran-
domized, controlled, phase 3 study comparing 
neoadjuvant chemoradiotherapy followed by sur-
gery with surgery alone in patients with poten-
tially curable esophageal or esophagogastric-
junction carcinoma.8
ME THODS
ELIGIBILITY CRITERIA
Patients with histologically confirmed, potentially 
curable squamous-cell carcinoma, adenocarci-
noma, or large-cell undifferentiated carcinoma of 
the esophagus or esophagogastric junction (i.e., 
tumors involving both the cardia and the esopha-
gus on endoscopy) were eligible for inclusion in 
the study. The upper border of the tumor had to be 
at least 3 cm below the upper esophageal sphincter. 
Patients who had proximal gastric tumors with 
minimal invasion of the esophagus were excluded. 
The length and width of the tumor could not ex-
ceed 8 cm and 5 cm, respectively. Only patients 
with tumors of clinical stage T1N1 or T2-3N0-1 
and no clinical evidence of metastatic spread 
(M0), according to the International Union 
against Cancer (UICC) tumor–node–metastasis 
(TNM) classification,9 were enrolled. Eligible pa-
tients were 18 to 75 years of age, had a World 
Health Organization (WHO) performance status 
score of 2 or lower (on a scale of 0 to 5, with 0 
indicating fully active, 1 unable to carry out 
heavy physical work, and 2 up and about more 
than half the day but unable to work), and had 
lost 10% or less of body weight. Patients also had 
to have adequate hematologic, renal, hepatic, and 
pulmonary function, as well as no history of other 
cancer or previous radiotherapy or chemotherapy.
All patients provided written informed consent. 
The institutional review board at each participating 
center approved the study protocol.8 The protocol, 
including the statistical analysis plan, is available 
with the full text of this article at NEJM.org. No 
commercial support was involved in the study; 
the drugs were purchased. No one who is not an 
author contributed to the manuscript. The first, 
fourth, and last authors vouch for the accuracy 
and completeness of the reported data and the 
fidelity of the study to the protocol.
STAGING
All patients underwent pretreatment staging. This 
included a history taking; physical examination; 
pulmonary-function tests, routine hematologic 
and biochemical tests; upper gastrointestinal en-
doscopy with histologic biopsy and endoscopic 
ultrasonography; computed tomography of the 
neck, chest, and upper abdomen; and external ul-
trasonography of the neck, with fine-needle aspi-
ration of lymph nodes when cancer was suspected. 
For the final analysis, the available endoscopic re-
ports were centrally reviewed.
TREATMENT
Chemotherapy
On days 1, 8, 15, 22, and 29, carboplatin targeted 
at an area under the curve of 2 mg per milliliter 
per minute and paclitaxel at a dose of 50 mg per 
square meter of body-surface area were adminis-
tered intravenously. All patients were intravenously 
premedicated with dexamethasone, clemastine, 
and ranitidine as well as standard antiemetic 
agents. The patients were closely monitored for 
toxic effects of chemotherapy with the use of the 
National Cancer Institute’s Common Terminolo-
gy Criteria for Adverse Events, version 3.0.10
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Radiotherapy
A total radiation dose of 41.4 Gy was given in 23 
fractions of 1.8 Gy each, with 5 fractions admin-
istered per week, starting on the first day of the 
first chemotherapy cycle. All patients were treated 
by means of external-beam radiation. A detailed 
description of the methods of administration of 
chemotherapy and radiotherapy can be found in 
Appendix 1 in the Supplementary Appendix, avail-
able at NEJM.org.
Surgery
Patients in the chemoradiotherapy–surgery group 
underwent surgery as soon as possible after com-
pletion of chemoradiotherapy (preferably, within 
4 to 6 weeks), and patients in the surgery group 
were treated as soon as possible after randomiza-
tion. A transthoracic approach with two-field 
lymph-node dissection was performed for tumors 
extending proximally to the tracheal bifurcation. 
For tumors involving the esophagogastric junction, 
a transhiatal resection was preferred. Peritruncal 
dissection was carried out with both approaches. 
For all other tumors, the approach depended on the 
characteristics of the patient and on local prefer-
ences. Gastric-tube reconstruction with a cervical 
anastomosis was the preferred technique for re-
storing the continuity of the digestive tract.
PATHOLOGICAL ANALYSIS
Reports on pathological examination had to de-
scribe the tumor type and extension, lymph nodes, 
and resection margins. In the absence of macro-
scopic tumor, any abnormal-appearing tissue 
was paraffin-embedded in total in order to make 
an adequate assessment for the presence of re-
sidual tumor and the effects of therapy.
To grade the response to therapy, we classified 
the degree of histomorphologic regression into 
four categories as follows: grade 1, no evidence of 
vital residual tumor cells (pathological complete 
response); grade 2, less than 10% vital residual 
tumor cells; grade 3, 10 to 50%; and grade 4, 
more than 50%.11,12 If a vital tumor was present 
at 1 mm or less from the proximal, distal, or cir-
cumferential resection margin, it was considered 
to be microscopically positive (R1).
FOLLOW-UP
During the first year after treatment was com-
pleted, patients were seen every 3 months. In the 
second year, follow-up took place every 6 months, 
and then at the end of each year until 5 years af-
ter treatment. Late toxic effects, disease recur-
rence, and death were documented. Recurrences 
were scored at the moment of the first recur-
rence. During follow-up, diagnostic investiga-
tions were performed only when recurrence was 
suspected.
STATISTICAL ANALYSIS
We calculated that 175 patients were needed in 
each group in order to detect a difference in me-
dian overall survival of 22 months in the chemo-
radiotherapy–surgery group versus 16 months in 
the surgery group (two-sided test; alpha level, 
0.05; beta level, 0.80). Stratification factors in-
cluded histologic tumor type, treatment center, 
lymph-node (N) stage as determined by endo-
scopic ultrasonography, and WHO performance 
score. Block randomization was performed cen-
trally by telephone or at the central trial office, 
368 Underwent randomization
837 Patients were assessed for esophageal
or EGJ cancer
469 Were excluded
2 Withdrew consent
7 Did not receive any 
chemoradiotherapy
180 Were assigned to chemo-
radiotherapy and surgery
188 Were assigned to surgery
alone
178 Were included
in the analysis
188 Were included
in the analysis
171 Received chemoradiotherapy
168 Underwent surgery
161 Underwent resection
186 Underwent surgery
161 Underwent resection
Figure 1. Study Enrollment.
Of the 368 patients who underwent randomization, 178 in the chemoradio-
therapy–surgery group and 188 in the surgery group were included in the 
intention-to-treat analysis. A resection was not possible in 7 patients in the 
chemoradiotherapy–surgery group and in 25 in the surgery group because 
the primary tumor or lymph nodes were identified as unresectable during 
surgery. EGJ denotes esophagogastric junction.
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according to computer-generated randomization 
lists for each stratum, with random block sizes 
of 4 or 6.
Data were analyzed according to the intention-
to-treat principle. The primary end point was 
overall survival. All other described outcomes 
were secondary end points. No post hoc analyses 
were performed. Survival was calculated from 
Table 1. Characteristics of Patients with Resectable Esophageal or Esophagogastric-Junction Cancer, According to 
Treatment Group.*
Characteristic
Chemoradiotherapy and Surgery
(N = 178)
Surgery Alone
(N = 188)
Age — yr
Median 60 60
Range 36–79 36–73
Male sex — no. (%) 134 (75) 152 (81)
Tumor type — no. (%)
Adenocarcinoma 134 (75) 141 (75)
Squamous-cell carcinoma 41 (23) 43 (23)
Other 3 (2) 4 (2)
Tumor length — cm†
Median 4 4
Interquartile range 3–6 3–6
Tumor location — no. (%)†
Esophagus
Proximal third 4 (2) 4 (2)
Middle third 25 (14) 24 (13)
Distal third 104 (58) 107 (57)
Esophagogastric junction 39 (22) 49 (26)
Missing data 6 (3) 4 (2)
Clinical T stage — no. (%)‡
cT1 1 (1) 1 (1)
cT2 26 (15) 35 (19)
cT3 150 (84) 147 (78)
cT4 0 1 (1)
Could not be determined§ 1 (1) 4 (2)
Clinical N stage — no. (%)¶
N0 59 (33) 58 (31)
N1 116 (65) 120 (64)
Could not be determined§ 3 (2) 10 (5)
WHO performance status score — no. (%)‖
0 144 (81) 163 (87)
1 34 (19) 25 (13)
* Percentages may not add up to 100 because of rounding. WHO denotes World Health Organization.
† Tumor length and location were determined by means of endoscopy.
‡ Clinical tumor (cT) stage was assessed by means of endoscopic ultrasonography or computed tomography (CT) and was 
classified according to the International Union against Cancer (UICC) tumor–node–metastasis (TNM) classification.9
§ This category included patients in whom the tumor could not be fully investigated by means of a transducer for endoscopic 
ultrasonography owing to a stenosis caused by the tumor.
¶ Clinical lymph-node (N) stage was assessed by means of endoscopic ultrasonography, CT, or 18F-fluorodeoxyglucose 
positron-emission tomography and was classified according to UICC TNM classification.9
‖ WHO performance status scores are on a scale of 0 to 5, with lower numbers indicating better performance status; 0 indi-
cates fully active, and 1 unable to carry out heavy physical work.
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the date of randomization until death. All data 
collected through December 2010 were included 
in the analysis, which guaranteed a potential 
minimal follow-up of 2 years.
The Kaplan–Meier method was used to esti-
mate survival, with the log-rank test to deter-
mine significance. A Cox proportional-hazards 
model was used to estimate the treatment effect 
with adjustment for prognostic factors for sur-
vival. Moreover, Cox models were used to iden-
tify possible interactions in treatment effect 
between subgroups, both with and without 
adjustment for prognostic factors. Subgroups 
were predefined according to sex, histologic 
subtype of tumor, clinical N stage, and WHO 
performance score. Statistical analysis was per-
formed with the use of SPSS software, version 
17.0 (SPSS).
R ESULT S
CHARACTERISTICS OF THE PATIENTS
From March 2004 through December 2008, we 
enrolled 368 patients in the study, of whom 180 
were randomly assigned to the chemoradiother-
apy–surgery group, and 188 to the surgery group. 
Two patients who were randomly assigned to 
the chemoradiotherapy–surgery group withdrew 
consent and were not included in the analysis 
(Fig. 1).
Prognostic factors were well balanced be-
tween the two treatment groups (Table 1). In 
both groups, the median age was 60 years; 134 
of 178 patients (75%) in the chemoradiotherapy–
surgery group were men, as compared with 152 
of 188 patients (81%) in the surgery group. Most 
patients (275 of 366 [75%]) had an adenocarci-
Table 2. Adverse Events during Neoadjuvant Chemoradiotherapy and after Surgery.*
Event
Chemoradiotherapy  
and Surgery
(N = 171)
Surgery Alone
(N = 186)
Postoperative events — no. of patients/total no. (%)†
Pulmonary complications‡ 78/168 (46) 82/186 (44)
Cardiac complications§ 36/168 (21) 31/186 (17)
Chylothorax¶ 17/168 (10) 11/186 (6)
Mediastinitis‖ 5/168 (3) 12/186 (6)
Anastomotic leakage** 36/161 (22) 48/161 (30)
Death
In hospital 6/168 (4) 8/186 (4)
After 30 days 4/168 (2) 5/186 (3)
Events of any grade during chemoradiotherapy — no. of patients (%)
Anorexia 51 (30)
Alopecia 25 (15)
Constipation 47 (27)
Diarrhea 30 (18)
Esophageal perforation 1 (1)
Esophagitis 32 (19)
Fatigue 115 (67)
Nausea 91 (53)
Neurotoxic effects 25 (15)
Vomiting 43 (25)
Leukopenia 103 (60)
Neutropenia 16 (9)
Thrombocytopenia 92 (54)
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noma. In both groups, the median tumor length 
was 4 cm. Most tumors were located in the dis-
tal esophagus (in 211 of 366 patients [58%]) or 
at the esophagogastric junction (in 88 [24%]). In 
the chemoradiotherapy–surgery group, 116 of 
178 patients (65%) had positive lymph nodes as 
determined by endoscopic ultrasonography, as 
compared with 120 of 188 (64%) in the surgery 
group.
DELIVERY AND TOXIC EFFECTS  
OF CHEMORADIOTHERAPY
Seven patients (4%) in the chemoradiotherapy–
surgery group did not receive any chemoradio-
therapy: 5 because of disease progression before 
commencing therapy and 2 because they de-
clined the therapy. A total of 162 patients (91%) 
received the full treatment regimen of five cycles 
of chemoradiotherapy, and 164 (92%) received 
the full dose of radiotherapy. Two patients (1%) 
received a higher dose of radiotherapy (45.0 and 
54.0 Gy, respectively). The most common reason 
for not completing all chemotherapy cycles was a 
low platelet count.
In 12 of 171 patients (7%) who received treat-
ment in the chemoradiotherapy–surgery group, 
grade 3 hematologic toxic effects were observed; 
a grade 4 hematologic toxic effect and neutrope-
nic fever developed in 1 patient. One patient died 
while awaiting surgery after chemoradiotherapy, 
probably owing to a perforation of the esopha-
gus, accompanied by major hemorrhage in the 
Table 2. (Continued.)
Event
Chemoradiotherapy  
and Surgery
(N = 171)
Surgery Alone
(N = 186)
Events of grade ≥3 during chemoradiotherapy — no. of patients (%)
Anorexia 9 (5)
Constipation 1 (1)
Diarrhea 2 (1)
Esophageal perforation 1 (1)
Esophagitis 2 (1)
Fatigue 5 (3)
Nausea 2 (1)
Vomiting 1 (1)
Leukopenia 11 (6)
Neutropenia 4 (2)
Thrombocytopenia 1 (1)
* Adverse events were graded according to the National Cancer Institute’s Common Terminology Criteria for Adverse 
Events, version 3.0.10
† Of the 171 patients who received treatment with chemoradiotherapy, 168 underwent surgery.
‡ Pulmonary complications were pneumonia (isolation of pathogen from sputum culture and a new or progressive infil-
trate on chest radiograph), serious atelectasis (lobar collapse on chest radiograph), pneumothorax (collection of air 
between the visceral and parietal pleural surfaces, requiring drainage), pleural effusion (collection of fluid between 
the visceral and parietal pleural surfaces, requiring drainage), pulmonary embolus (embolus detected on spiral CT or 
a ventilation–perfusion mismatch on a lung scintigram), and acute respiratory failure (partial pressure of arterial oxy-
gen <60 mm Hg while breathing ambient air).
§ Cardiac complications were arrhythmia (any change in rhythm on the electrocardiogram, requiring treatment), myo-
cardial infarction (two or three of the following: previous myocardial infarction, electrocardiographic changes suggest-
ing myocardial infarction, or enzyme changes suggesting myocardial infarction), and left ventricular failure (marked 
pulmonary edema on a chest radiograph).
¶ Chylothorax was recorded when elevated levels of triglycerides in intrathoracic fluid (>1 mmol per liter [89 mg per 
deciliter]) were found.
‖ Mediastinitis was scored when reported by the local investigator.
** Anastomotic leakages were recorded when they were diagnosed on physical or radiologic examination in the patients 
who underwent resection. Leakage was classified as subclinical if it was diagnosed on radiologic examination or en-
doscopy and as clinical if a salivary fistula was present.
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absence of thrombocytopenia. All other major 
nonhematologic toxic effects of grade 3 or higher 
occurred in less than 13% of patients in this 
group. All serious adverse events that occurred 
during treatment are summarized in Table 2.
SURGERY
In the chemoradiotherapy–surgery group, 168 
patients (94%) underwent surgery, as compared 
with 186 (99%) in the surgery group (P = 0.01). 
Reasons for not undergoing surgery were the pa-
tient’s decision (2 patients in the chemoradio-
therapy–surgery group), disease progression dur-
ing treatment (7 in the chemoradiotherapy–surgery 
group and 1 in the surgery group), diagnosis of a 
second cancer before surgery (1 in the surgery 
group), and death before surgery due to toxic ef-
fects of chemoradiotherapy (1). No patients were 
considered medically unfit for surgery.
The median time between randomization and 
surgery was 97 days in the chemoradiotherapy–
surgery group and 24 days in the surgery group. 
The median time between the end of chemora-
diotherapy and surgery was 6.6 weeks (inter-
quartile range, 5.7 to 7.9). In 7 of 168 patients (4%) 
in the chemoradiotherapy–surgery group, a re-
section was not possible because the primary 
tumor or lymph nodes were identified during sur-
gery as unresectable, as compared with 25 of 186 
patients (13%) in the surgery group (P = 0.002).
Postoperative complications are summarized 
in Table 2. No significant differences in the occur-
rence of complications were found between the 
two treatment groups. Six of 168 patients (4%) in 
the chemoradiotherapy–surgery group died in the 
hospital, as did 8 of 186 (4%) in the surgery group 
(P = 0.70). Four patients (2%) in the chemoradio-
therapy–surgery group died within 30 days after 
surgery, as compared with 5 (3%) in the surgery 
group (P = 0.85).
PATHOLOGICAL ASSESSMENT
An R0 resection was achieved in 148 of 161 patients 
(92%) in the chemoradiotherapy–surgery group, 
as compared with 111 of 161 (69%) in the surgery 
group (P<0.001). A pathological complete response 
(ypT0N0; y denotes underwent neoadjuvant chemo-
radiotherapy, and p denotes by pathological assess-
ment) was seen in the resection specimens from 47 
patients (29%) in the chemoradiotherapy–surgery 
group. A pathological complete response was ob-
served in 28 of 121 patients with adenocarcino-
ma (23%) versus 18 of 37 with squamous-cell 
carcinoma (49%) (P = 0.008). A median of 15 lymph 
nodes were resected in patients in the chemora-
diotherapy–surgery group, as compared with 18 in 
patients in the surgery group (P = 0.77). One or 
more positive lymph nodes in the resection spec-
imen were found in 50 patients (31%) in the 
chemoradiotherapy–surgery group, as compared 
with 120 patients (75%) in the surgery group 
(P<0.001). The pathological findings in all resec-
tion specimens are summarized in Appendix 2 in 
the Supplementary Appendix.
SURVIVAL
For surviving patients, the median follow-up was 
45.4 months (range, 25.5 to 80.9). Of the 61 pa-
tients in the chemoradiotherapy–surgery group 
who underwent resection and died after having 
been discharged, 52 (85%) died from recurrent 
cancer and 9 (15%) from other causes (2 from 
sepsis, 2 from cardiac failure, 2 from respiratory 
insufficiency, 1 from kidney failure, 1 from a sec-
ond primary tumor, and 1 after reconstructive 
surgery for a persistent postoperative neo-esoph-
agotracheal fistula). Of the 83 patients in the sur-
gery group who underwent resection and died 
after having been discharged, 78 (94%) died 
from recurrent cancer, 4 (5%) from other causes 
(2 from cardiac failure, 1 from respiratory fail-
ure, and 1 from a thromboembolic event), and 1 
from an unknown cause (P = 0.14). The median 
disease-free survival for patients who underwent 
resection was not reached in the chemoradio-
therapy–surgery group and was 24.2 months in 
the surgery group (hazard ratio, 0.498; 95% con-
fidence interval [CI], 0.357 to 0.693; P<0.001).
An intention-to-treat analysis that included 
all patients showed a median overall survival of 
49.4 months in the chemoradiotherapy–surgery 
group versus 24.0 months in the surgery group 
(P = 0.003 by the log-rank test; hazard ratio, 
0.657; 95% CI, 0.495 to 0.871) (Fig. 2A). The re-
spective overall survival rates at 1, 2, 3, and 5 
years were 82%, 67%, 58%, and 47% in the 
chemoradiotherapy–surgery group, as compared 
with 70%, 50%, 44%, and 34% in the surgery 
group. Adjustment for baseline prognostic fac-
tors led to a similar effect estimate (hazard ra-
tio, 0.665; 95% CI, 0.500 to 0.884).
Separate curves for overall survival according 
to histologic subtype (i.e., adenocarcinoma or 
squamous-cell carcinoma) are shown in Figure 
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2B. The benefit of neoadjuvant chemoradiother-
apy on survival was consistent across subgroups, 
without any significant interaction identified. 
Hazard ratios for the subgroup effects, with and 
without adjustment for baseline covariates, are 
shown in Figure 3.
DISCUSSION
This large, randomized trial of neoadjuvant 
chemoradiotherapy in patients with esophageal 
or esophagogastric-junction cancer showed sig-
nificantly better overall and disease-free survival 
among patients who received a chemoradiothera-
py regimen based on carboplatin and paclitaxel, 
followed by surgery, as compared with those 
treated with surgery alone. The chemoradiotherapy 
was associated with a low frequency of high-grade 
toxic effects and could be given as an outpatient 
treatment. The preoperative treatment did not result 
in higher postoperative morbidity or early mortality 
in this group, as compared with the surgery group. 
Patients treated with neoadjuvant chemoradio-
therapy followed by surgery had a 34% lower risk 
of death during follow-up (hazard ratio, 0.657).
The chemoradiotherapy regimen was designed 
on the basis of our experience in a previous phase 
2 study,7 which used the same dosages of radio-
therapy and chemotherapy. In that study, it was 
possible to administer this regimen on an out-
patient basis, and all the patients had resection 
margins that were microscopically negative. On 
the basis of these results, an alteration of the 
chemoradiotherapy regimen was not thought to 
be necessary.
The present study was designed to detect a 
difference in median survival of 6 months in 
favor of the combined regimen of chemoradio-
therapy and surgery, as compared with surgery 
alone (22 months vs. 16 months). The observed 
survival in both groups was superior to the an-
ticipated survival and to that reported in earlier 
randomized trials.6,13-17 In line with the results 
of other studies, the survival of patients treated 
with surgery alone has improved,18,19 probably 
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Figure 2. Kaplan–Meier Plots of Estimated Overall 
5-Year Survival.
Panel A shows a Kaplan–Meier plot of the estimated 
overall 5-year survival among patients with esophageal 
or esophagogastric-junction cancer who underwent neo-
adjuvant chemoradiotherapy (CRT) followed by surgery 
(178 patients) or surgery alone (188), according to an 
intention-to-treat analysis. Panel B shows a Kaplan–
Meier plot of the estimated overall 5-year survival 
among the 134 patients with adenocarcinoma (AC) 
treated with neoadjuvant chemoradiotherapy followed 
by surgery and the 141 treated with surgery alone, and 
the 41 patients with squamous-cell carcinoma (SCC) 
treated with chemoradiotherapy followed by surgery 
and the 43 treated with surgery alone, according to an 
intention-to-treat analysis. Other tumor types were ex-
cluded from this analysis.
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owing to ongoing improvements in surgical tech-
niques, patient selection, and staging methods 
over the years. The difference in overall survival 
in the present study is not due to poor survival 
in the surgery group but can clearly be attributed 
to improved survival in the chemoradiotherapy–
surgery group.
In the chemoradiotherapy–surgery group, 94% 
of patients underwent surgery, and 90% of tu-
mors could be resected. In the surgery group, 
99% of patients underwent surgery, and 86% 
underwent resection. These percentages indicate 
that the preoperative chemoradiotherapy did not 
significantly change the individual chance of 
undergoing a resection.14,15,17 Postoperative com-
plication rates, although similar between groups, 
were higher than expected and higher than re-
ported in other studies.20 We could not find a 
plausible explanation for this finding, other than 
the fact that all postoperative events were meticu-
lously recorded. This relatively high incidence of 
postoperative events in both treatment groups 
did not result in an increased postoperative mor-
tality, which was low and similar in the two 
groups.
Complete remission in both the primary tu-
mor and the lymph nodes (ypT0N0) was the best 
possible pathological outcome of chemoradio-
therapy. The observed percentage of patients 
with a pathological complete response (29%) is 
in line with the reported percentages in other 
phase 2 and phase 3 studies.7,13,14,18,21 The sub-
stantial downstaging as a result of chemoradio-
therapy is also reflected in the significantly 
higher percentage of R0 resections in the chemo-
radiotherapy–surgery group.
Despite the higher rate of pathological com-
plete response among patients with squamous-
cell carcinoma, as compared with those with 
adenocarcinoma, histologic tumor type was not 
a prognostic factor for survival. That is, patients 
with adenocarcinoma and patients with squa-
mous-cell carcinoma both benefited from neo-
adjuvant chemoradiotherapy.
Whether esophageal and esophagogastric-
junction tumors should be treated with preop-
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Figure 3. Hazard Ratios for Death.
This forest plot shows hazard ratios for death (oblongs) and 95% confidence intervals (I bars) for 366 patients with 
esophageal or esophagogastric-junction cancer, according to baseline characteristics. Univariate hazard ratios are 
shown, as well as hazard ratios adjusted for baseline covariates. Clinical lymph-node (N) stage was assessed by 
means of endoscopic ultrasonography, computed tomography, or 18F-fluorodeoxyglucose positron-emission tomog-
raphy and classified according to the International Union against Cancer (UICC) tumor–node–metastasis (TNM) 
classification.9
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erative chemoradiotherapy or with perioperative 
chemotherapy, as suggested by the Medical Re-
search Council Adjuvant Gastric Infusional Che-
motherapy (MAGIC) trial22 and the Actions 
Concertées dans les Cancer Colorectaux et Di-
gestifs (ACCORD) 07 trial,23 is unclear. Both 
trials included gastric tumors as well as esopha-
gogastric-junction tumors, whereas in the cur-
rent trial only patients with esophageal or 
esophagogastric-junction tumors were treated. 
In the POET trial, only patients with esophago-
gastric-junction tumors were included and ran-
domly assigned to preoperative chemotherapy or 
chemoradiotherapy.24 In that study, there was a 
nonsignificant trend in favor of preoperative 
chemoradiotherapy. Because a substantial per-
centage of patients in the chemoradiotherapy–
surgery group in the present study (22%) had an 
esophagogastric-junction tumor, we favor preop-
erative chemoradiotherapy for such patients, as 
was also suggested by the POET study, espe-
cially because of the limited toxic effects that 
were observed with this treatment regimen. In 
conclusion, preoperative chemoradiotherapy (five 
courses of carboplatin and paclitaxel, with 41.4 Gy 
of concurrent radiotherapy) is safe and leads to 
a significant increase in overall survival among 
patients with adenocarcinoma or squamous-cell 
carcinoma of the esophagus or esophagogastric 
junction.
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